NASDAQ: AYTU
Aytu Biopharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for AYTU

Based on 2 analysts offering 12 month price targets for Aytu Biopharma Inc

Min Forecast
$7.00+169.23%
Avg Forecast
$10.00+284.62%
Max Forecast
$13.00+400%

Should I buy or sell AYTU stock?

Based on 2 analysts offering ratings for Aytu Biopharma Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AYTU stock forecasts and price targets.

AYTU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-10
lockedlocked$00.00+00.00%2025-09-25

1 of 1

Forecast return on equity

Is AYTU forecast to generate an efficient return?

Company
20.63%
Industry
279.99%
Market
237.79%
AYTU's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AYTU forecast to generate an efficient return on assets?

Company
3.82%
Industry
152.75%
AYTU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AYTU earnings per share forecast

What is AYTU's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.16
Avg 2 year Forecast
-$0.26
Avg 3 year Forecast
$0.47

AYTU revenue forecast

What is AYTU's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$56.4M-11.5%
Avg 2 year Forecast
$83.0M+30.37%
Avg 3 year Forecast
$92.3M+44.86%
AYTU's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AYTU revenue growth forecast

How is AYTU forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
10.52%
Industry
363.65%
Market
56.5%
AYTU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AYTU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AYTU vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
AYTU$2.60$10.00+284.62%Strong Buy
BGM$3.53N/AN/A
TXMD$2.16N/AN/A
APUS$1.85N/AN/A
SCYX$0.71$3.00+321.94%Strong Buy

Aytu Biopharma Stock Forecast FAQ

Is Aytu Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AYTU) stock is to Strong Buy AYTU stock.

Out of 2 analysts, 1 (50%) are recommending AYTU as a Strong Buy, 1 (50%) are recommending AYTU as a Buy, 0 (0%) are recommending AYTU as a Hold, 0 (0%) are recommending AYTU as a Sell, and 0 (0%) are recommending AYTU as a Strong Sell.

If you're new to stock investing, here's how to buy Aytu Biopharma stock.

What is AYTU's earnings growth forecast for 2026-2028?

(NASDAQ: AYTU) Aytu Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 774.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.53%.

Aytu Biopharma's earnings in 2026 is -$13,071,000.On average, 5 Wall Street analysts forecast AYTU's earnings for 2026 to be -$11,846,848, with the lowest AYTU earnings forecast at -$11,881,488, and the highest AYTU earnings forecast at -$11,660,404. On average, 5 Wall Street analysts forecast AYTU's earnings for 2027 to be -$2,597,993, with the lowest AYTU earnings forecast at -$5,890,822, and the highest AYTU earnings forecast at $962,786.

In 2028, AYTU is forecast to generate $4,780,307 in earnings, with the lowest earnings forecast at $4,592,844 and the highest earnings forecast at $4,920,904.

What is AYTU's revenue growth forecast for 2026-2028?

(NASDAQ: AYTU) Aytu Biopharma's forecast annual revenue growth rate of 10.52% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 363.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 56.5%.

Aytu Biopharma's revenue in 2026 is $63,696,000.On average, 5 Wall Street analysts forecast AYTU's revenue for 2026 to be $574,288,909, with the lowest AYTU revenue forecast at $520,811,005, and the highest AYTU revenue forecast at $652,554,722. On average, 5 Wall Street analysts forecast AYTU's revenue for 2027 to be $846,028,792, with the lowest AYTU revenue forecast at $699,644,620, and the highest AYTU revenue forecast at $1,093,296,600.

In 2028, AYTU is forecast to generate $940,076,140 in revenue, with the lowest revenue forecast at $903,215,204 and the highest revenue forecast at $967,726,937.

What is AYTU's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: AYTU) forecast ROA is 3.82%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 152.75%.

What is AYTU's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AYTU price target, the average AYTU price target is $10.00, with the highest AYTU stock price forecast at $13.00 and the lowest AYTU stock price forecast at $7.00.

On average, Wall Street analysts predict that Aytu Biopharma's share price could reach $10.00 by Dec 10, 2026. The average Aytu Biopharma stock price prediction forecasts a potential upside of 284.62% from the current AYTU share price of $2.60.

What is AYTU's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AYTU) Aytu Biopharma's current Earnings Per Share (EPS) is -$2.19. On average, analysts forecast that AYTU's EPS will be -$1.16 for 2026, with the lowest EPS forecast at -$1.17, and the highest EPS forecast at -$1.14. On average, analysts forecast that AYTU's EPS will be -$0.26 for 2027, with the lowest EPS forecast at -$0.58, and the highest EPS forecast at $0.09. In 2028, AYTU's EPS is forecast to hit $0.47 (min: $0.45, max: $0.48).

What is AYTU's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: AYTU) forecast ROE is 20.63%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.